Full-Time

Director / Senior Director – GCP Quality Assurance Lead

Prilenia

Prilenia

51-200 employees

Develops pridopidine treatments for neurodegenerative diseases

No salary listed

Boston, MA, USA

Remote

Occasional international travel within US and Europe.

Bachelor's, Master's, PharmD, PhD

Category
QA & Testing
Required Skills
Google Cloud Platform

Get referred to Prilenia

See people who can refer or advise you

Requirements
  • Bachelor’s degree or higher in life sciences, pharmacy, or a related discipline; advanced degree (MSc, PharmD) preferred.
  • Minimum 10 years of GCP QA experience within the pharmaceutical, biotechnology, or CRO industry, with at least 3 years in a leadership or director-level role at a biotech company.
  • Demonstrated expertise across GCP, GvP, and GLP quality frameworks; hands-on experience conducting and managing audits in all three domains.
  • Deep knowledge of ICH E6(R2/R3), ICH E2 series, FDA 21 CFR Parts 11/50/54/56/312, EU Clinical Trials Regulation (No. 536/2014), EU GvP modules, and OECD Principles of GLP.
  • Proven experience leading or managing regulatory authority inspections (FDA, EMA, MHRA, or equivalent) to successful outcomes.
  • Experience building or significantly maturing a QMS in a small-to-mid-size pharmaceutical setting.
  • Proficiency with eTMF systems (e.g., Veeva Vault, Wingspan) and electronic QMS platforms.
  • Exceptional communication skills; able to translate complex regulatory requirements into clear guidance for diverse audiences.
  • Highly autonomous, proactive, and resilient; comfortable in a fast-paced, resource-efficient environment.
Responsibilities
  • Ensure all Prilenia-sponsored trials are conducted, documented, and reported in compliance with applicable regulations, ICH guidelines, and Prilenia's SOPs.
  • Serve as Prilenia's day-to-day QA lead for Phase 3 clinical operations, embedded in the program team from protocol review through clinical study report sign-off.
  • Act as sponsor QA counterpart to CRO QA teams and to Ferrer's QA function, maintain quality oversight of outsourced trial execution, align on standards, and manage issue escalation.
  • Oversee eTMF quality, manage protocol deviations and GxP non-conformances, drive CAPA resolution with CROs and sites, and maintain continuous inspection readiness.
  • Lead inspection readiness and management for regulatory authority inspections (FDA, EMA, MHRA, PMDA); serve as primary QA contact, coordinate responses to observations, and oversee regulatory commitment closure.
  • Author and maintain GCP and related SOPs; define and track quality metrics and KPIs for senior leadership.
  • Oversee clinical site, CRO, and vendor audits; review reports, manage CAPA resolution; review and approve Quality Agreements.
  • Serve as GVP QA partner and SME to Drug Safety: oversee PV systems, vendor quality performance, and vendor audits; support CAPA resolution for safety findings; ensure compliance with EU GvP modules, FDA 21 CFR Part 312, and ICH E2 series.
  • Serve as GLP QA partner and SME for externally conducted pre-clinical studies; ensure compliance with OECD Principles of GLP and applicable national regulations.
  • Contribute to Prilenia's fit-for-purpose QMS, SOP lifecycle, quality event tracking, training, and regulatory intelligence.
  • Represent QA on clinical program teams and relevant governance forums.
  • Champion a proactive quality and compliance culture, making quality an enabler of clinical program success rather than a compliance exercise.
  • Mentor junior QA staff and foster professional development within the quality function.
Desired Qualifications
  • Experience in neurology, neurodegenerative disease, or rare disease clinical programs.
  • Familiarity with risk-based monitoring (RBM), centralized monitoring, and ICH E6(R3) risk-proportionate approaches.
  • Professional certification: RQAP-GCP (SQA), RAC (RAPS), CCRA (ACRP), or equivalent.
  • Experience supporting NDA/BLA/MAA submissions and post-approval quality oversight.
  • Knowledge of 21 CFR Part 11 / Annex 11 (computerized systems) and data integrity principles (ALCOA+)

Prilenia develops and commercializes medicines for brain diseases. It focuses on creating treatments for neurodegenerative conditions (like Huntington’s disease and ALS) and neurodevelopmental disorders. Its main candidate is pridopidine, a drug studied to help brain cells by activating the sigma-1 receptor (S1R), which researchers believe can help restore brain pathways impaired in these diseases. The product works by engaging S1R to support neuronal function, with the goal of slowing symptoms or progression once approved. Prilenia aims to stand out by its specific focus on S1R biology, building a pipeline of potential therapies, and bringing these treatments to patients through regulatory approval and commercialization. The company’s goal is to provide validated therapies that address urgent needs for patients and families affected by neurodegenerative and neurodevelopmental disorders, while growing its team and expanding its pipeline for future medicines.

Company Size

51-200

Company Stage

Series B

Total Funding

$115.5M

Headquarters

Herzliya, Israel

Founded

2018

Get referred to Prilenia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PRECISE-HD started July 7, 2026, and PREVAiLS enrolled first patients March 30, 2026.
  • Prilenia's May 26, 2026 CHDI data-sharing deal strengthens HD credibility and external validation.
  • The April 28, 2026 CFO hire shows financing discipline heading into expensive Phase 3 execution.

What critics are saying

  • EMA withdrew Nurzigma in November 2025, proving Europe rejected pridopidine without more data.
  • Prilenia remains a single-asset company; PRECISE-HD and PREVAiLS failure kills the platform.
  • ALS and HD enrollments in 2026 create a multi-year cash burn before any approval.

What makes Prilenia unique

  • Prilenia’s pridopidine targets sigma-1 receptor biology across Huntington’s disease and ALS.
  • Ferrer’s April 2025 license gives Prilenia ex-U.S. commercialization reach and non-dilutive milestones.
  • PRECISE-HD and PREVAiLS make Prilenia one of few companies running two Phase 3 brain-disease trials.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Wellness Program

Mental Health Support

Conference Attendance Budget

Family Planning Benefits

Fertility Treatment Support

Stock Options

401(k) Retirement Plan

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

8%
Associated Press
Apr 28th, 2026
Prilenia names Dr. Elisabeth Leiderman as CFO to lead financial strategy through Phase 3 trials

Prilenia Therapeutics, a biopharmaceutical company focused on Huntington's disease and Amyotrophic Lateral Sclerosis treatments, has appointed Dr Elisabeth Leiderman as Chief Financial Officer. Leiderman brings over 20 years of finance and corporate development experience in life sciences. She has previously served as CFO at multiple biotech companies including Dewpoint, Atsena and Decibel, and currently sits on the board of Autolus Therapeutics. She also held senior investment banking positions at UBS, Credit Suisse and Nomura. The appointment comes as Prilenia embarks on two Phase 3 studies for its drug pridopidine in HD and ALS. Leiderman will focus on managing the company's financial runway through Phase 3 completion whilst preparing for potential commercialisation.

AIJourn
Apr 28th, 2025
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets

NAARDEN, Netherlands & WALTHAM, Mass. - (BUSINESS WIRE) - Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets.

BioSpace
Sep 19th, 2024
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer

Prilenia appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer.

Business Wire
Apr 12th, 2024
Prilenia To Present Latest Research From Its Pridopidine Programs For Huntington Disease And Als At Aan 2024

NAARDEN, Netherlands WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced the presentation of the latest research from the pridopidine Huntington disease (HD) and amyotrophic lateral sclerosis (ALS) programs at the American Academy of Neurology (AAN) Annual Congress, in Denver, Colorado, April 13-18. “Pridopidine is now in pre-registration phase in HD, with a first submission planned Mid 2024i, and is also set to commence a global Phase 3 study in ALS later this year. We are making significant strides forward and this is reflected by presentation of the data at one of the most important medical congresses in the field of Neurology,” said Jina Swarz, MD. Ph.D., the recently appointed Chief Medical Officer of Prilenia. “Pridopidine is one of the most advanced investigational new drugs in HD and ALS and has shown consistent treatment benefits across independent measures that are important to patients and families. The presented data advances knowledge in the field, providing important learnings for both clinical practice and for the design of our programs going forward

Business Wire
Mar 12th, 2024
Prilenia Plans To Submit Marketing Authorization Application (Maa) In The Eu For Pridopidine In Huntington’S Disease

NAARDEN, Netherlands WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, announced its plan to submit a Marketing Authorization Application (MAA) for pridopidine for the treatment of Huntington’s disease (HD) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). This decision follows positive pre-submission meetings with regulatory authorities in the European Union. Submission is planned for mid-2024. “Pridopidine demonstrates consistent treatment benefits across independent measures that are important to patients and families. These measures include day-to-day function, cognition, motor and clinical progression in people living with HD. The benefits are clearly evident in those with HD who are not taking anti-dopaminergic medications (ADM),” said Dr